Skip to main content

Table 1 Procedures in the Identification study

From: Study protocol: DexaDays-2, hydrocortisone for treatment of dexamethasone-induced neurobehavioral side effects in pediatric leukemia patients: a double-blind placebo controlled randomized intervention study with cross-over design

Day

1

2

3

4

5

6

7

8

Timepoint Procedure

T1

    

T2

 

T2a

Standard medication

 Dexamethasone

X

X

X

X

X

   

 Vincristine

X

       

 Methotrexate

X

      

X

Questionnaires

 SDQ

X

    

X

  

 SDSC

X

    

X

  

 PSI

X

    

X

  

 DT

X

       

 DT (short)

     

X

  

 Support

X

       

 Support (short)

     

X

  

 Eating thermometer

X

    

X

  

Blood sample

 Genetics

X

       

 Dexa peak level

X

       

 Dexa trough level

     

X

 

X

Somatic parameters

        

 Weight

X

    

X

 

X

 Height

X

    

X

 

X

 Blood pressure

X

    

X

 

X

Done at (h = home / H = hospital)

H

h

h

h

h

H

h

H

  1. The Identification study is the cohort from which eligible candidates for the Randomized Controlled Trial are selected. T1 = start dexamethasone. T2 = after 5 days of dexamethasone. T2a = 2 days after stop dexamethasone. See Fig. 1 for a schematic overview
  2. SDQ  Strengths and difficulties questionnaire, SDSC Sleep disturbance scale for children, PSI  Parenting stress index, DT  Distress thermometer, PedsQL Pediatric quality of life questionnaire
Back to article page

BMC Pediatrics

ISSN: 1471-2431

Contact us